EGFR and non-small cell lung carcinoma: In view of a possible functional interaction between the ER and the epidermal growth factor receptor (EGFR) pathways in NSCLC, fulvestrant has also been evaluated in combination with EGFR tyrosine-kinase inhibitors (TKIs), both in NSCLC xenografts [4,9] and in women with NSCLC [18], with promising results.